CAS 2381089-83-2
|
Product Name |
CAS 2381089-83-2 |
|
CAS Number |
2381089-83-2 |
|
Appearance |
White powder |
|
Purity(HPLC) |
≥98.0% |
|
Acetate content |
≤12.0% |
|
Endotoxin |
≤50EU/m |
|
Moisture content |
≤8.0% |
|
Peptide content |
≥80.0% |
|
Amino acid composition analysis |
≤±10% |
|
Storage method |
freeze-drying at -20℃ and storage away from light |
|
Note |
For research purposes only, not for human use |
CAS number 2381089-83-2 corresponds to the substance Retatrutide (LY3437943), which is described in detail below,
Advantages
Efficient Metabolic Regulation: Retatrutide simultaneously targets multiple receptors such as GLP-1, GIP, and glucagon receptors. This triple action mechanism optimizes glucose metabolism more effectively than many single-receptor-targeting drugs. It promotes insulin secretion postprandially, curbing blood sugar spikes, and regulates hepatic glucose output, maintaining stable blood glucose levels, which is highly beneficial for type 2 diabetes patients.
Significant Weight Loss Aid: Beyond glycemic control, it has shown remarkable potential in weight management. Clinical trials have reported substantial weight reduction in participants, making it an attractive option for obese patients or those with weight-related comorbidities, often outperforming some traditional weight-loss medications.
Potential Cardiovascular Benefits: There is emerging evidence suggesting that Retatrutide may confer protection against cardiovascular diseases. By improving lipid profiles, reducing inflammation in blood vessels, and enhancing overall metabolic health, it could lower the risk of heart attacks and strokes in patients with metabolic disorders.
Enhanced Patient Compliance: Thanks to its multitargeted effects, patients may need fewer medications to manage multiple health issues simultaneously. This simplifies treatment regimens, increasing the likelihood of patients adhering to the prescribed therapy, which is crucial for long-term health management.
Disadvantages
Gastrointestinal Side Effects
The most commonly reported drawback is mild to moderate gastrointestinal discomfort. Patients may experience nausea, vomiting, diarrhea, or abdominal pain, especially during the initial stages of treatment. These symptoms can be distressing and might lead some patients to consider discontinuing the drug if not properly managed.
Limited Long-Term Data
Despite promising short-term and mid-term results, the long-term safety and efficacy of Retatrutide remain relatively uncharted. Extended use over decades could potentially unmask rare but serious side effects, and its impact on overall health and quality of life in the long run requires further investigation.
Cost Implications
Newly developed drugs with advanced mechanisms often come with a hefty price tag. The high cost of Retatrutide may limit its accessibility to a broader patient population, particularly those without comprehensive insurance coverage, posing a barrier to equitable healthcare.
Complexity of Use
Given its potent effects on multiple physiological pathways, proper dosing and patient monitoring are more intricate. Healthcare providers need to closely assess patients' responses, adjust dosages meticulously, and be vigilant about potential drug interactions, adding complexity to the clinical management process.
In conclusion, Retatrutide holds great promise with its array of advantages, but its drawbacks cannot be overlooked. Rigorous research and clinical experience accumulation are essential to maximize its benefits while minimizing the associated risks and limitations.
Hot Tags: cas 2381089-83-2, China cas 2381089-83-2 manufacturers, suppliers, factory, Antibacterial Water, Cagrilintide-15mg, CAS 70 18 8, CAS 910463 68 2, retatrutide, Semax Powder